Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Neurology

Building Your Care Team and Preparing for Visits

At a Glance

People with GMPPB-related limb-girdle muscular dystrophy benefit from a coordinated neuromuscular care team. Bring the full genetic report, laboratory and nerve-test records, biopsy materials, and anesthesia history to help specialists plan monitoring and support.

Because GMPPB-related disease is an ultra-rare condition that can affect the muscles, nerves, heart, and lungs, a single doctor is rarely enough to manage all aspects of your care. The gold standard for treatment is a multidisciplinary care team—a group of specialists who work together to coordinate your monitoring and therapy [1][2].

Your Multidisciplinary Team

A coordinated neuromuscular center is the best place to find this team. Your core team should typically include:

  • Neuromuscular Specialist (Neurologist): The central physician who manages the diagnosis and monitors muscle strength [3][4].
  • Cardiologist: Specifically one with experience in neuromuscular disease, to monitor your heart rhythm and function [5][6].
  • Pulmonologist: To monitor your breathing strength and sleep health [7][8].
  • Genetic Counselor: Essential for explaining your specific GMPPB mutations. They will also discuss reproductive risks: for two carrier parents, each pregnancy has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected [3][9].
  • Physical and Occupational Therapists (PT/OT): To help you maintain mobility and adapt your environment for safety and independence [10][11].
  • Other Specialists: Depending on your symptoms, you may also need a neuro-ophthalmologist (for eye issues), an epileptologist (if seizures occur), or a speech-language pathologist (if you have trouble swallowing) [12][13].

Preparing for Your Consultation

When visiting a new specialist or a major academic medical center, bringing the actual raw data is far better than bringing just a summary note [4][14].

Gather these items into a dedicated medical binder:

  1. Full Genetic Test Report: This must include the specific names of your mutations (e.g., c.79G>C) and the variant classifications [3][9].
  2. CK Lab Trends: A list of your creatine kinase levels over time [5][15].
  3. EMG and RNS Reports: The full technical report from your nerve tests [16][2].
  4. Muscle Biopsy Materials: The actual glass slides or digital images, as specialists may want to re-examine the staining themselves [12][14].
  5. Anesthesia History: A list of any past surgeries and how you reacted to the medications used [17].

Finding the Right Expertise

Look for specialists who focus on congenital muscular dystrophies (CMD) or congenital myasthenic syndromes (CMS) [3][16].

  • Specialized Networks: Networks and professional organizations like TREAT-NMD or the European Neuromuscular Centre (ENMC) often link the world’s leading experts [18].
  • Patient Registries: Ask your genetic counselor about enrolling in national or disease-specific registries. While enrollment does not guarantee access to clinical trials, it helps researchers find eligible patients and can keep you updated on new discoveries [19][20]. Be sure to discuss privacy considerations when joining.
  • Academic Medical Centers: Large university hospitals with dedicated Neuromuscular Centers are most likely to have the necessary multidisciplinary staff under one roof [2][21].

Common questions in this guide

Which specialists should be on a GMPPB-related muscular dystrophy care team?
A coordinated neuromuscular team usually includes a neuromuscular neurologist, cardiologist, pulmonologist, genetic counselor, and physical and occupational therapists. Depending on symptoms, an eye specialist, seizure specialist, or speech-language pathologist may also be helpful.
What records should I bring to a GMPPB specialist visit?
Bring the complete genetic test report, including the exact variants and how they are classified, along with creatine kinase (CK) results over time. Also bring full EMG and repetitive nerve stimulation reports, muscle biopsy slides or digital images, and a record of past anesthesia reactions.
How can I find specialists who know about GMPPB-related disease?
Look for a coordinated neuromuscular center, especially at an academic medical center with experience in congenital muscular dystrophies or congenital myasthenic syndromes. Organizations such as TREAT-NMD and the European Neuromuscular Centre can help identify specialized expertise.
What can genetic counseling explain for my family?
A genetic counselor can review your GMPPB variants, explain how the condition may be inherited, and coordinate testing for relatives. When both parents are carriers of a relevant GMPPB variant, each pregnancy has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected.
Can I join a GMPPB registry or natural history study?
Ask your genetic counselor or neuromuscular specialist about disease registries, natural history studies, and clinical trials. Joining a registry does not guarantee trial access, but it may help researchers identify eligible participants and keep you informed about new research; ask about privacy before enrolling.

Get notified when new evidence is published on GMPPB-related limb-girdle muscular dystrophy R19.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    Limb-Girdle Muscular Dystrophies.

    Liewluck T

    Continuum (Minneapolis, Minn.) 2025; (31(5)):1344-1371 doi:10.1212/cont.0000000000001615.

    PMID: 41037170
  2. 2

    Congenital myasthenic syndrome due to novel GFPT1 variant presenting with head drop and visual impairment: A case report.

    Torrey K, Logan R, Tiongson E, et al.

    Journal of neuromuscular diseases 2026; (13(6)):1557-1563 doi:10.1177/22143602261457200.

    PMID: 42247610
  3. 3

    GDP-Mannose Pyrophosphorylase B (GMPPB)-Related Disorders.

    Chompoopong P, Milone M

    Genes 2023; (14(2)) doi:10.3390/genes14020372.

    PMID: 36833299
  4. 4

    Genetic and Clinical Advances of Congenital Muscular Dystrophy.

    Fu XN, Xiong H

    Chinese medical journal 2017; (130(21)):2624-2631 doi:10.4103/0366-6999.217091.

    PMID: 29067961
  5. 5

    Mutations in GMPPB Presenting with Pseudometabolic Myopathy.

    Panicucci C, Fiorillo C, Moro F, et al.

    JIMD reports 2018; (38()):23-31 doi:10.1007/8904_2017_25.

    PMID: 28456886
  6. 6

    2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders.

    Groh WJ, Bhakta D, Tomaselli GF, et al.

    Heart rhythm 2022; (19(10)):e61-e120 doi:10.1016/j.hrthm.2022.04.022.

    PMID: 35500790
  7. 7

    Comparison of sitting and supine forced vital capacity in collagen VI-related dystrophy and laminin α2-related dystrophy.

    Meilleur KG, Linton MM, Fontana J, et al.

    Pediatric pulmonology 2017; (52(4)):524-532 doi:10.1002/ppul.23622.

    PMID: 28085238
  8. 8

    LMNA-Related Muscular Dystrophy with Clinical Intrafamilial Variability.

    Cotta A, Paim JF, Carvalho E, et al.

    Journal of molecular neuroscience : MN 2019; (69(4)):623-627 doi:10.1007/s12031-019-01390-0.

    PMID: 31410651
  9. 9

    Whole-Exome Sequencing in Undiagnosed Muscular Dystrophies: A High Diagnostic Yield and Novel Insights From Iranian Families.

    Soltani N, Shahbazi Z, Fallah MS, et al.

    Human mutation 2026; (2026()):6592066 doi:10.1155/humu/6592066.

    PMID: 42553504
  10. 10

    Orthopedic and Surgical Management of the Patient With Duchenne Muscular Dystrophy.

    Apkon SD, Alman B, Birnkrant DJ, et al.

    Pediatrics 2018; (142(Suppl 2)):S82-S89 doi:10.1542/peds.2018-0333J.

    PMID: 30275252
  11. 11

    Rehabilitation Management of the Patient With Duchenne Muscular Dystrophy.

    Case LE, Apkon SD, Eagle M, et al.

    Pediatrics 2018; (142(Suppl 2)):S17-S33 doi:10.1542/peds.2018-0333D.

    PMID: 30275246
  12. 12

    GMPPB-Associated Dystroglycanopathy: Emerging Common Variants with Phenotype Correlation.

    Jensen BS, Willer T, Saade DN, et al.

    Human mutation 2015; (36(12)):1159-63 doi:10.1002/humu.22898.

    PMID: 26310427
  13. 13

    Clinical presentations and pathophysiological mechanisms of dystroglycanopathy: advancing therapeutic strategies.

    Walimbe AS, Muntoni F, Campbell KP

    The Lancet. Neurology 2026; (25(7)):689-700 doi:10.1016/S1474-4422(26)00191-2.

    PMID: 42309089
  14. 14

    Compound heterozygous CAPN3 variants identified in a family with limb-girdle muscular dystrophy recessive 1.

    Zhang C, Zheng X, Lu D, et al.

    Molecular medicine reports 2021; (23(6)).

    PMID: 33899113
  15. 15

    Muscular Dystrophy: A Retrospective Evaluation of 15 Cases.

    Güngör O, Dilber C

    Sisli Etfal Hastanesi tip bulteni 2018; (52(1)):47-50 doi:10.14744/SEMB.2017.53496.

    PMID: 32595371
  16. 16

    Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies.

    Belaya K, Rodríguez Cruz PM, Liu WW, et al.

    Brain : a journal of neurology 2015; (138(Pt 9)):2493-504 doi:10.1093/brain/awv185.

    PMID: 26133662
  17. 17

    Anaesthetic management of patients with myopathies.

    Schieren M, Defosse J, Böhmer A, et al.

    European journal of anaesthesiology 2017; (34(10)):641-649 doi:10.1097/EJA.0000000000000672.

    PMID: 28719515
  18. 18

    International collaboration to improve knowledge on myotonic dystrophy type 2.

    Peric S, Ivanovic V, Ashley EJ, et al.

    Journal of neuromuscular diseases 2024; (11(6)):1229-1237 doi:10.1177/22143602241290353.

    PMID: 39973464
  19. 19

    The Canadian Neuromuscular Disease Registry 2010-2019: A Decade of Facilitating Clinical Research Througha Nationwide, Pan-NeuromuscularDisease Registry.

    Hodgkinson V, Lounsberry J, M'Dahoma S, et al.

    Journal of neuromuscular diseases 2021; (8(1)):53-61 doi:10.3233/JND-200538.

    PMID: 32925088
  20. 20

    The New Zealand Neuromuscular Disease Patient Registry; Five Years and a Thousand Patients.

    Rodrigues MJ, O'Grady GL, Hammond-Tooke G, et al.

    Journal of neuromuscular diseases 2017; (4(3)):183-188 doi:10.3233/JND-170240.

    PMID: 28800337
  21. 21

    Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network.

    Shimizu R, Ogata K, Tamaura A, et al.

    BMC health services research 2016; (16()):241 doi:10.1186/s12913-016-1477-4.

    PMID: 27401940

This page offers general information about organizing care for GMPPB-related muscular dystrophy and preparing for appointments; it does not replace medical advice. Ask your neuromuscular team to interpret your records and recommend monitoring for your situation.

Guide contents GMPPB-related limb-girdle muscular dystrophy R19
Research & Literature
05 Long-Term Monitoring and Your Surveillance Plan